2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
283
Breast
21
Tumor-Agnostic
12
Gastrointestinal
11
Thoracic
10
Gynecologic
7
Other solid neoplasm
5
Lymphoid
4
Head & Neck
4
Dermatologic
4
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Prostatic Neoplasms
1
Liposarcoma
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
Radiotherapy
220
Doxorubicin
210
Cyclophosphamide
210
Temozolomide
182
Ifosfamide
121
Filgrastim
111
Imatinib Mesylate
104
Etoposide
101
Vincristine
92
Gemcitabine
89
Bevacizumab
83
Magnetic Resonance Spectroscopy
80
Irinotecan
79
pembrolizumab
75
Radiation
69
Carboplatin
65
Methotrexate
62
pazopanib
61
Nivolumab
58
Cisplatin
58
fludarabine phosphate
57
Peripheral Blood Stem Cell Transplantation
57
Surgical Procedures, Operative
56
Specimen Handling
56
Trabectedin
52
Docetaxel
50
Biopsy
50
Busulfan
49
Melphalan
46
Paclitaxel
44
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
enzalutamide
×
Sarcoma
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled